


LEAD ENDOCRINOLOGY PROGRAM

Lead Value Driver

CETRORELIX

An innovative treatment
in Phase 3 clinical trials for
benign prostatic hyperplasia



BPH

A large market opportunity¹

- › Affects one out of three men over the age of 50/one out of two over 60
- › Affects 20 million men in the U.S. alone
- › Represents a \$1.4 billion market in the U.S. alone

BPH is a benign enlargement of the prostate which is very common in men over 50.

Symptoms include:

- › Frequent need to urinate
- › Urgency during the night
 - › Difficulty urinating
 - › Painful urination
- › Residual urine in the bladder
- › Engorged kidneys

CETRORELIX is leading a novel class of compounds (LHRH antagonists) being developed for the treatment of BPH. Compared with existing treatments, cetorelix has shown in clinical trials to date to be unique because it reduces the symptoms of BPH without causing sexual side effects such as loss of libido and erectile dysfunction. We believe cetorelix also has the potential to offer patients better convenience and compliance compared to existing therapies. Cetorelix is being developed for twice-yearly intramuscular injection regimens while current treatments require daily, oral dosing regimens.

PHASE 3 PROGRAM

- › 1,500 patients in North America and Europe
- › Results expected in the second half of 2009

¹ (Sources: BPH, *Urologic Diseases in America, 2004*; NIH publication 04-5512:43-67)